Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial
Open Access
- 18 December 2024
- journal article
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 133, 55-63
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma
- Novartis Pharmaceuticals Corporation
- Research Council of Norway (273563)
This publication has 48 references indexed in Scilit:
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Blood Pressure Components and End-stage Renal Disease in Persons With Chronic Kidney DiseaseArchives of internal medicine (1960), 2012
- Blood Pressure Targets for Patients with Diabetes or Kidney DiseaseCurrent Hypertension Reports, 2011
- Effect of atorvastatin on kidney function in chronic kidney disease: A randomised double-blind placebo-controlled trialAtherosclerosis, 2010
- Elevated Blood Pressure and Risk of End-stage Renal Disease in Subjects Without Baseline Kidney DiseaseArchives of internal medicine (1960), 2005
- Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertensionAmerican Journal of Hypertension, 2003
- Effects of Blood Pressure Level on Progression of Diabetic NephropathyResults From the RENAAL StudyArchives of internal medicine (1960), 2003
- Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney DiseaseResults From the AASK TrialJAMA, 2002
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- A Prospective Study of Blood Pressure and Serum CreatinineJAMA, 1993